{"title":"Myelopeptides: new immunoregulatory peptides.","authors":"R Petrov","doi":"10.2500/108854195778666784","DOIUrl":null,"url":null,"abstract":"<p><p>Bone marrow cells of various animal species and humans produce a group of bioregulatory peptides called myelopeptides (MPs). MPs have been isolated and purified, and their physico-chemical properties have been investigated. MPs have a wide spectrum of functional activities: immunoregulatory, differentiating, and opiate-like. A new immunocorrective drug, Myelopidum, which is used effectively in clinical practice for treating diseases accompanied by immunodeficiency, has been created on the basis of MPs. Administration of Myelopidum after surgery prevents 50% to 70% of postsurgical complications, particularly postsurgery pneumonia, and also normalizes the number and balance of T-helper cells, T-suppressor cells, and B-lymphocytes in patients with chronic pulmonary diseases, resulting in a beneficial clinical effect, including a significant prolongation of remission periods. Myelopidum is also used in veterinary medicine for prophylaxis and treatment of pneumonia and enteritis in newborn and young animals. The primary structure of several myelopeptides is established. The functional activities of two, MP-1 (Phe-Leu-Gly-Phe-Pro-Thr) and MP-2 (Leu-Val-Val-Tyr-Pro-Trp), are being investigated.</p>","PeriodicalId":7423,"journal":{"name":"Allergy proceedings : the official journal of regional and state allergy societies","volume":"16 4","pages":"177-84"},"PeriodicalIF":0.0000,"publicationDate":"1995-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2500/108854195778666784","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergy proceedings : the official journal of regional and state allergy societies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2500/108854195778666784","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Bone marrow cells of various animal species and humans produce a group of bioregulatory peptides called myelopeptides (MPs). MPs have been isolated and purified, and their physico-chemical properties have been investigated. MPs have a wide spectrum of functional activities: immunoregulatory, differentiating, and opiate-like. A new immunocorrective drug, Myelopidum, which is used effectively in clinical practice for treating diseases accompanied by immunodeficiency, has been created on the basis of MPs. Administration of Myelopidum after surgery prevents 50% to 70% of postsurgical complications, particularly postsurgery pneumonia, and also normalizes the number and balance of T-helper cells, T-suppressor cells, and B-lymphocytes in patients with chronic pulmonary diseases, resulting in a beneficial clinical effect, including a significant prolongation of remission periods. Myelopidum is also used in veterinary medicine for prophylaxis and treatment of pneumonia and enteritis in newborn and young animals. The primary structure of several myelopeptides is established. The functional activities of two, MP-1 (Phe-Leu-Gly-Phe-Pro-Thr) and MP-2 (Leu-Val-Val-Tyr-Pro-Trp), are being investigated.
各种动物和人类的骨髓细胞产生一组称为髓肽(MPs)的生物调节肽。对MPs进行了分离纯化,并对其理化性质进行了研究。MPs具有广泛的功能活动:免疫调节、分化和鸦片样。在MPs的基础上,研制出了一种新的免疫矫正药物髓鞘(Myelopidum),在临床实践中有效地用于治疗伴有免疫缺陷的疾病。术后给予髓鞘可预防50% - 70%的术后并发症,特别是术后肺炎,并使慢性肺部疾病患者的t辅助细胞、t抑制细胞和b淋巴细胞的数量和平衡正常化,产生有益的临床效果,包括显著延长缓解期。髓鞘也用于兽医预防和治疗新生儿和幼龄动物的肺炎和肠炎。确定了几种髓肽的初级结构。MP-1 (Phe-Leu-Gly-Phe-Pro-Thr)和MP-2 (leu - val - val - tir - pro - trp)的功能活性正在研究中。